Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ELLEN J SCHLETTE and WILLIAM G WIERDA.
Connection Strength

0.538
  1. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
    View in: PubMed
    Score: 0.100
  2. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma. 2009 Oct; 50(10):1597-605.
    View in: PubMed
    Score: 0.087
  3. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
    View in: PubMed
    Score: 0.055
  4. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.055
  5. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma. 2021 05; 62(5):1129-1135.
    View in: PubMed
    Score: 0.047
  6. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.
    View in: PubMed
    Score: 0.045
  7. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. 2019 Sep; 12(3):161-165.
    View in: PubMed
    Score: 0.038
  8. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 01; 123(18):2783-90.
    View in: PubMed
    Score: 0.030
  9. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010 Nov; 23(11):1518-23.
    View in: PubMed
    Score: 0.023
  10. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71.
    View in: PubMed
    Score: 0.021
  11. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7.
    View in: PubMed
    Score: 0.020
  12. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.